Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1.
Host genome is still poorly investigated in the context of vaccine or immunotherapy, however recently findings emphasized that it may affect the response to those treatments. In our retrospective study we evaluated the effect of HIV-1 genetic restriction factors on the response to dendritic cell (DC)-based immunotherapy in a Brazilian cohort of HIV positive (HIV+) patients that underwent a phase I clinical trial in 2004. Genomic DNA from 18 HIV+ individuals that underwent DC-based immunotherapy was analyzed for selected polymorphisms known to be associated with susceptibility to HIV-1 infection and/or AIDS progression. Allelic and genotypic distribution of the 22 polymorphisms was evaluated considering the response to the treatment. The rs11884476 SNP in PARD3B resulted associated with good response to immune treatment according to an over-dominant model. Even if functional effect of this variation is still unknown, our data suggested that it could play a role in the control of viral replication. Our findings, being aware of the limitation represented by the small number of subjects analyzed, suggest that genetic factors involved in AIDS progression could affect the response to immunotherapy, reinforcing the idea that deeper investigation on host genetic variations will be fundamental for a rational vaccine development.
Department of Immunology; Institute of Biologic Sciences; University of Sao Paulo; Sao Paulo, Brazil.
Alessandra
A
Pontillo
Department of Genetics; Federal University of Pernambuco; Recife, Brazil.
Ronaldo C
RC
Da Silva
Department of Genetics; Federal University of Pernambuco; Recife, Brazil.
Ronald
R
Moura
Department of Genetics; Federal University of Pernambuco; Recife, Brazil.
Sergio
S
Crovella
D000328:Adult; D001938:Brazil; D002352:Carrier Proteins / Q000235:genetics; D003713:Dendritic Cells / Q000276:immunology*; D004198:Disease Susceptibility; D005260:Female; D005787:Gene Frequency; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008565:Membrane Proteins / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies; D016896:Treatment Outcome
D002352:Carrier Proteins; D008565:Membrane Proteins; C471157:PARD3B protein, human
DC-based immune-treatment; HIV vaccine; PARD3B; host genome and response to vaccine